Evidence map›Paper›PMID 29206881›Full record

ArticlePloS one2017

Deletion of lynx1 reduces the function of α6* nicotinic receptors.

Rell L Parker, Heidi C O'Neill, Beverley M Henley, Charles R Wageman, Ryan M Drenan, Michael J Marks, Julie M Miwa, Sharon R Grady, Henry A Lester

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rell L ParkerDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States of America.
Heidi C O'NeillInstitute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, United States of America.
Beverley M HenleyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States of America.
Charles R WagemanInstitute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, United States of America.
Ryan M DrenanDepartment of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
Michael J MarksInstitute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, United States of America.
Julie M MiwaDepartment of Biological Sciences, Lehigh University, Bethlehem, PA, United States of America.
Sharon R GradyInstitute for Behavioral Genetics, University of Colorado Boulder, Boulder, CO, United States of America.
Henry A LesterDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, United States of America.ORCID http://orcid.org/0000-0002-5470-5255
University of Colorado Boulder · USCalifornia Institute of Technology · USLehigh University · USNorthwestern University · US

Funding

Project 3 University of Colorado, BoulderU19DA019375 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI MARKS, MICHAEL J · 2005 to 2014
$8.3M
GENETICS OF NICOTINE TOLERANCE: ROLE OF RECEPTORSR01DA003194 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI MARKS, MICHAEL J · 1985 to 2013
$5.5M
Studies with Nicotinic Null Mutant MiceP30DA015663 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI MARKS, MICHAEL J · 2003 to 2013
$4.5M
Nicotinic acetylcholine receptor function in the mesolimbic dopamine systemR01DA035942 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DRENAN, RYAN MICHAEL · 2014 to 2023
$3.9M
Alpha4 Nicotinic Receptor in Addiction: Mouse ModelsR01DA017279 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI LESTER, HENRY A. · 2004 to 2014
$3.5M
ALPHA-CONOTOXIN MII--SELECTIVE NICOTINIC RECEPTOR PROBER01DA012242 · NIDA · UNIVERSITY OF COLORADO AT BOULDER · PI WHITEAKER, PAUL · 1999 to 2011
$3.5M
Development of a5 nicotinic receptor agonists for smoking cessationR44DA032464 · NIDA · OPHIDION, INC. · PI ANGENIEUX, BRIGITTE · 2015 to 2016
$793k
Alpha6* nAChRs in Dopamine Transmission and Nicotine DependenceR00DA030396 · NIDA · PURDUE UNIVERSITY · PI DRENAN, RYAN MICHAEL · 2011 to 2013
$709k
Lynx in organization and dynamics of nicotinic acetylcholine receptor complexesR21DA033831 · NIDA · LEHIGH UNIVERSITY · PI LESTER, HENRY A., MAYOR, SATYAJIT · 2012 to 2013
$439k
In vivo and in vitro tools to target CHRNA5 for smoking cessation.R41DA032464 · NIDA · OPHIDION, INC. · PI ANGENIEUX, BRIGITTE · 2011 to 2011
$296k
Alpha6* nAChRs in Dopamine Transmission and Nicotine DependenceK99DA030396 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DRENAN, RYAN MICHAEL · 2010 to 2010
$90k
NIDA NIH HHS K99 DA030396NIDA NIH HHS P30 DA015663NIDA NIH HHS R00 DA030396NIDA NIH HHS R01 DA003194NIDA NIH HHS R01 DA012242NIDA NIH HHS R01 DA017279NIDA NIH HHS R01 DA035942NIDA NIH HHS R21 DA033831NIDA NIH HHS R41 DA032464NIDA NIH HHS R44 DA032464NIDA NIH HHS U19 DA019375
6 · The paper itself

Abstract

The α6 nicotinic acetylcholine receptor (nAChR) subunit is an attractive drug target for treating nicotine addiction because it is present at limited sites in the brain including the reward pathway. Lynx1 modulates several nAChR subtypes; lynx1-nAChR interaction sites could possibly provide drug targets. We found that dopaminergic cells from the substantia nigra pars compacta (SNc) express lynx1 mRNA transcripts and, as assessed by co-immunoprecipitation, α6 receptors form stable complexes with lynx1 protein, although co-transfection with lynx1 did not affect nicotine-induced currents from cell lines transfected with α6 and β2. To test whether lynx1 is important for the function of α6 nAChRs in vivo, we bred transgenic mice carrying a hypersensitive mutation in the α6 nAChR subunit (α6L9'S) with lynx1 knockout mice, providing a selective probe of the effects of lynx1 on α6* nAChRs. Lynx1 removal reduced the α6 component of nicotine-mediated rubidium efflux and dopamine (DA) release from synaptosomal preparations with no effect on numbers of α6β2 binding sites, indicating that lynx1 is functionally important for α6* nAChR activity. No effects of lynx1 removal were detected on nicotine-induced currents in slices from SNc, suggesting that lynx1 affects presynaptic α6* nAChR function more than somatic function. In the absence of agonist, lynx1 removal did not alter DA release in dorsal striatum as measured by fast scan cyclic voltammetry. Lynx1 removal affected some behaviors, including a novel-environment assay and nicotine-stimulated locomotion. Trends in 24-hour home-cage behavior were also suggestive of an effect of lynx1 removal. Conditioned place preference for nicotine was not affected by lynx1 removal. The results show that some functional and behavioral aspects of α6-nAChRs are modulated by lynx1.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsDopamineGPI-Linked ProteinsHEK293 CellsHumansMiceMice, TransgenicNeuronsReceptors, NicotinicRNA, MessengerAdaptor Proteins, Signal TransducingDopamineGPI-Linked ProteinsLYNX1 protein, humannicotinic receptor alpha6Receptors, NicotinicRNA, Messenger

Identifiers

PMID29206881
PMCPMC5716591
OpenAlexW2772216643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.